PTC THERAPEUTICS INC (PTCT) 41.49 +1.14 (+2.83%)
41.49 +1.14 (+2.83%)
US69366J2006 - Common Stock - After market: 41.49 0 (0%)
Fundamental Rating
Overall PTCT gets a fundamental rating of 3 out of 10. We evaluated PTCT against 631 industry peers in the Biotechnology industry. PTCT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PTCT is valued expensive at the moment.
Profitability
Profitability Rating
PTCT's Return On Assets of -33.71% is amongst the best of the industry. PTCT does better than the industry average Return On Assets of -44.83%.
PTCT has a Profit Margin of -76.28%. This is better than the industry average of -464.10%.
The profitability ratios for PTCT are negative, so there is not much use analyzing them.
The Piotroski-F score of PTCT is 2.00. This is a very weak score and indicates problems in health and profitability for PTCT.
VS Industry
ROA (-33.71%) VS Industry: 65% outperformed.
-950.38
52.28
Profit Margin (-76.28%) VS Industry: 75% outperformed.
-1,173,705.71
34,743.00
Valuation
Valuation Rating
The Price/Earnings Ratio is negative for PTCT. In the last year negative earnings were reported.
Also next year PTCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry
Growth
Growth Rating
PTCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.53%.
Measured over the past 5 years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 45.46% on average per year.
PTCT is expected to show quite a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 15.12% yearly.
The Earnings Per Share is expected to grow by 9.54% on average over the next 5 years.
The earnings per share for PTCT have decreased strongly by -15.28% in the last year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -15.28% | 16.41% | 23% | 21.92% | 9.54% |
| Revenue | 45.46% | 26.72% | 41.53% | 40.08% | 28.81% | 22.64% | 15.12% |
Health
Health Rating
A Current Ratio of 1.23 indicates that PTCT should not have too much problems paying its short term obligations.
PTCT has a Quick Ratio of 1.20. This is a normal value and indicates that PTCT is financially healthy and should not expect problems in meeting its short term obligations.
PTCT has a Altman-Z score comparable to the industry average, which is at -0.81.
Compared to an average industry Current Ratio of 6.16, PTCT is worse placed to pay its short term obligations than its industry peers. 93% of its industry peers have a better Current Ratio.
When comparing the Quick Ratio of PTCT to the average industry Current Ratio of 6.05, PTCT is less able to pay its short term obligations than its industry peers. 92% of its industry peers have a better Quick Ratio.
PTCT has a negative Debt to Equity ratio (-4.33), which implies it has negative shareholder equity as the company's liabilities exceed its assets. This could be considered a sign of high risk.
Based on the Altman-Z score of -1.42, we must say that PTCT is in the distress zone and has some risk of bankruptcy.
The Piotroski-F score of PTCT is 2.00. This is a very weak score and indicates problems in health and profitability for PTCT.
VS Industry
Quick Ratio (1.2) VS Industry: 8% outperformed.
0.02
84.53
Current Ratio (1.23) VS Industry: 7% outperformed.
0.02
85.09
Altman-Z (-1.42) VS Industry: 47% outperformed.
-135.10
443.02
Dividend
Dividend Rating
No dividends for PTCT!.
PTC THERAPEUTICS INC41.49
NASDAQ:PTCT (11/30/2022, 7:00:01 PM)+1.14 (+2.83%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 10-27 2022-10-27/amc | Earnings (Next) | 02-20 2023-02-20 |
| Ins Owners | 0.8% | Inst Owners | 105.76% |
| Market Cap | 2.98B | Analysts | 76 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 4.28 | P/B | N/A |
| EV/EBITDA | -15.65 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -15.28% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 19.05% |
| EPS Next Y | 16.41% | EPS Next 2Y | 23% |
| EPS Next 3Y | 21.92% | EPS Next 5Y | 9.54% |
| Revenue growth 1Y | 41.53% | Revenue growth 3Y | 26.72% |
| Revenue growth 5Y | 45.46% | Revenue growth Q2Q | 56.5% |
| Revenue Next Year | 40.08% | Revenue Next 2Y | 28.81% |
| Revenue Next 3Y | 22.64% | Revenue Next 5Y | 15.12% |
| Current Ratio | 1.23 | Quick Ratio | 1.2 |
| Altman-Z | -1.42 | F-Score | 2 |
| Debt/Equity | -4.33 | WACC | 8.43% |
| ROIC/WACC | N/A | ||
| ROA | -33.71% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | -76.28% | OM | -47.63% |
| Asset Turnover | 0.44 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA